microdosing glp-1 benefits GLP-1s: How (and Why) It Works Thinking About Microdosing GLP-1? 5

Hruby and Mac Hadley (University of Arizona, USA) in 19871989 Original development program Competitive Technologies Palatin Technologies , later spun off into PT-141 (bremelanotide) Target: non-selective agonist of MC1R, MC3R, MC4R, MC5R (more potent than -MSH, longer half-life) Standard experimental dose in human tanning studies: 0.025 mg/kg subcutaneously (Dorr 1996) In Dorr 1996 (n=10): increase in skin melanin density measured by colorimetry by ~25 % after a 10-day course Main adverse effects in the preclinical literature: nausea, flushing, hyperpigmentation (including atypical nevi), priapism Approximately 100+ publications in PubMed

, ,

Weekly GLP-1 medications have longer half-lives, meaning side effects take longer to resolve after stopping

AOD9604 is a synthetic peptide derived from a fragment of human growth hormone (HGH), specifically amino acids 177191 of the HGH molecule

Can it replace food sources

If symptoms persist, consult a healthcare professional